<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Recent evidence suggests that soluble oligomeric amyloid-β (Aβ) assemblies are critically involved in the pathogenesis of <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> (AD) </plain></SENT>
<SENT sid="1" pm="."><plain>We have generated a conformation-dependent monoclonal antibody (9D5) that selectively recognizes low-molecular weight AβpE3 oligomers, and demonstrated its diagnostic and therapeutic potential </plain></SENT>
<SENT sid="2" pm="."><plain>Here, we further characterize the specificity of this antibody by evaluating a spectrum of <z:hpo ids='HP_0002180'>neurodegeneration</z:hpo>-related protein deposits for cross-reactivity, and by comparing the staining pattern of 9D5 with a generic Aβ antibody that targets a linear <z:chebi fb="0" ids="53000">epitope</z:chebi> (mAb NT244), and with another conformation-dependent Aβ antibody that selectively labels amyloid fibrils of various molecular weights (pAb OC) </plain></SENT>
<SENT sid="3" pm="."><plain>The 9D5 antibody does not cross-react with other aggregated protein deposits in brains of <z:e sem="disease" ids="C0038868" disease_type="Disease or Syndrome" abbrv="PSNP1">progressive supranuclear palsy</z:e>, <z:e sem="disease" ids="C0393570" disease_type="Disease or Syndrome" abbrv="">corticobasal degeneration</z:e>, argyrophilic grain <z:e sem="disease" ids="C0236642" disease_type="Disease or Syndrome" abbrv="">disease, Pick's</z:e> disease, <z:e sem="disease" ids="C0030567" disease_type="Disease or Syndrome" abbrv="PD">Parkinson's disease</z:e>, <z:hpo ids='HP_0000726'>dementia</z:hpo> with <z:hpo ids='HP_0100315'>Lewy bodies</z:hpo>, multiple system <z:mpath ids='MPATH_127'>atrophy</z:mpath>, <z:e sem="disease" ids="C0751072" disease_type="Mental or Behavioral Dysfunction" abbrv="FTLD">frontotemporal lobar degeneration</z:e> or <z:hpo ids='HP_0007354'>amyotrophic lateral sclerosis</z:hpo> with TDP-43 inclusions, <z:e sem="disease" ids="C0022336" disease_type="Disease or Syndrome" abbrv="">Creutzfeldt-Jakob disease</z:e>, and vessel changes in <z:e sem="disease" ids="C0270786" disease_type="Disease or Syndrome" abbrv="">Binswanger</z:e> <z:hpo ids='HP_0001298'>encephalopathy</z:hpo>, demonstrating the specificity of 9D5 for Aβ deposits </plain></SENT>
<SENT sid="4" pm="."><plain>While NT244 and OC showed a comparable plaque load, 9D5 detected only approximately 15% of the total Aβ plaque load in the entorhinal cortex, the CA1 region, and the temporal neocortex </plain></SENT>
<SENT sid="5" pm="."><plain>Our study further supports a possible therapeutic advantage of 9D5 by the highly specific recognition of an <z:chebi fb="0" ids="53000">epitope</z:chebi> found only in oligomeric assemblies of AβpE3 of AD patients </plain></SENT>
<SENT sid="6" pm="."><plain>Moreover, selective binding to only a pathogenetically relevant fraction of Aβ deposits serves as rationale for passive immunization with 9D5-derivatives by limiting potential side effects of vaccination due to dissolvement of existing amyloid deposits </plain></SENT>
</text></document>